Compositions and methods for treatment and prevention of hyperuricemia related health consequences
View Patent ↗Disclosed herein are methods of delaying the onset or treating diabetes that comprises administering a uric acid lowering agent. The inventors have made the remarkable discovery that elevated uric acid levels are not a corollary to insulin resistance, but rather a primary mediator of insulin resistance. Specifically exemplified are methods that involve administering to a patient susceptible to development of diabetes a composition comprising a uric acid lowering agent in a regimen that maintains serum uric acid levels below at least 5.5 mg/dl, or below at least 5.2 mg/dl.
1. A method of improving nitric oxide bioavailability in renal arteriole and glomerular cells to treat uric acid-induced diabetic nephropathy in a patient in need, wherein said patient in need has diabetes, a uric acid level higher than 5.5 mg/dl, impaired endothelial function, and elevated albumin excretion, said method comprising administering to said patient a composition comprising a uric acid lowering agent (UALA) according to a regimen effective to maintain said patient's average serum uric acid level at or below 5.5 mg/dl and to increase nitric oxide bioavailability in renal arteriole and glomerular cells, wherein said UALA is a xanthine oxidase inhibitor.
2. The method of claim 1 , wherein said xanthine oxidase inhibitor is allopurinol or febuxostat, or both.
3. The method of claim 1 , wherein said regimen is effective to maintain said patient's average serum uric acid level at or below 5.5 mg/dl for at least 12 weeks.